Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 14/20 | 0.37 |
| ▸ | CNR2 | P34972 | 10/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5654053 | 0.93 | CNR1 (0.37) | HTTCNR1CNR2 | |
| SCHEMBL5652381 | 0.92 | CNR1 (0.36) | HTTCNR1CNR2 | |
| SCHEMBL5651630 | 0.90 | MEN1 (0.41) | — | |
| SCHEMBL5651564 | 0.88 | HTT (0.41) | HTTCNR1 | |
| SCHEMBL5654014 | 0.88 | HPSE (0.40) | HTTCNR1CNR2 | |
| SCHEMBL5650010 | 0.82 | HTT (0.40) | HTTCNR1CNR2 | |
| SCHEMBL5647407 | 0.80 | CNR1 (0.41) | CNR1CNR2 | |
| SCHEMBL5649151 | 0.79 | HDAC6 (0.45) | HTTCNR1 | |
| SCHEMBL5652259 | 0.79 | PRSS12 (0.47) | CNR1CNR2 | |
| SCHEMBL5648451 | 0.78 | CHEK2 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220769-B2 | Azolylbenzamides and analogues and their use for treating osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2007-05-22 | — | — | US | disclosed |
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | 3-V BIOSCIENCES, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | NR0B2, NR0B1, NCOR1 | HTT 4354/4885CNR1 68/4885CNR2 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.